Literature DB >> 11509628

The affinity of integrin alpha(4)beta(1) governs lymphocyte migration.

D M Rose1, V Grabovsky, R Alon, M H Ginsberg.   

Abstract

The interaction of integrin alpha(4)beta(1) with endothelial VCAM-1 controls the trafficking of lymphocytes from blood into peripheral tissues. Cells actively regulate the affinity of alpha(4)beta(1) for VCAM-1 (activation). To investigate the biological function of alpha(4)beta(1) activation, we isolated Jurkat T cell lines with defective alpha(4)beta(1) activation. Using these cells, we found that alpha(4)beta(1)-stimulated alpha(L)beta(2)-dependent cell migration was dramatically reduced in cells with defects in alpha(4)beta(1) activation. These cells required 20 times more VCAM-1 to promote alpha(L)beta(2)-dependent cell migration. This defect was at the level of alpha(4)beta(1) affinity as an activating alpha(4)beta(1) Ab rescued alpha(4)beta(1)-stimulated alpha(L)beta(2)-dependent migration. In contrast, migration of alpha(4)beta(1) activation-defective cells on VCAM-1 alone was enhanced at higher VCAM-1 densities. Thus, alpha(4)beta(1) activation determines a set point or threshold at which VCAM-1 can regulate alpha(L)beta(2)-dependent as well as alpha(4)beta(1)-dependent cell migration. Changes in this set point may specify preferred anatomical sites of integrin-dependent leukocyte emigration from the bloodstream.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509628     DOI: 10.4049/jimmunol.167.5.2824

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  A small molecule that inhibits the interaction of paxillin and alpha 4 integrin inhibits accumulation of mononuclear leukocytes at a site of inflammation.

Authors:  Christiane Kummer; Brian G Petrich; David M Rose; Mark H Ginsberg
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

3.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

4.  VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.

Authors:  Oisun Jung; DeannaLee M Beauvais; Kristin M Adams; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2019-10-28       Impact factor: 5.285

Review 5.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

6.  Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.

Authors:  Ken-Yu Lin; Dan Lu; Chien-Fu Hung; Shiwen Peng; Lanqing Huang; Chunfa Jie; Francisco Murillo; Jesse Rowley; Ya-Chea Tsai; Liangmei He; Dae-Jin Kim; Elizabeth Jaffee; Drew Pardoll; T-C Wu
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.

Authors:  Wells S Brown; Jahan S Khalili; Tania G Rodriguez-Cruz; Greg Lizee; Bradley W McIntyre
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

Review 8.  The role of integrins in glaucoma.

Authors:  Mark S Filla; Jennifer A Faralli; Jennifer L Peotter; Donna M Peters
Journal:  Exp Eye Res       Date:  2016-05-13       Impact factor: 3.467

9.  Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.

Authors:  Pamela S Becker; Kenneth J Kopecky; Adrianne N Wilks; Sylvia Chien; John M Harlan; Cheryl L Willman; Stephen H Petersdorf; Derek L Stirewalt; Thalia Papayannopoulou; Frederick R Appelbaum
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

10.  Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site.

Authors:  Chloé C Féral; David M Rose; Jaewon Han; Norma Fox; Gregg J Silverman; Kenneth Kaushansky; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2006-02-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.